Business
Helix BioPharma Reports on 2008 Annual General Meeting and Provides Corporate Update
AURORA, Ontario, Dec. 16 /CNW/ -- Helix BioPharma Corp. (TSX, FSE: HBP) reports that at its Annua...
About this update from Helix Biopharma Corp.
[{"type":"text","content":"\n\n\n\nAURORA, Ontario, Dec. 16 /CNW/ -- Helix BioPharma Corp. (TSX, FSE: HBP)\nreports that at its Annual General Meeting held today, shareholders\noverwhelmingly approved all of management's proposals.\n\n\n\nAnnual General Meeting Results\n\n\n\nAll seven Board members were re-elected as directors, with the Board\ncontinuing to be constituted of:\n\n\n\n\n\n\nDonald H. Segal Chairman of the Board and Chief Executive Officer\nKenneth A. Cawkell Director and Corporate Secretary\nJohn Docherty Director and President\nThomas Hodgson Director\nJack Kay Director\nGordon M. Lickrish Director\nSlawomir Majewski Director\n\n\nKPMG LLP was re-appointed as the Company's auditor.\n\n\n\nThe shareholders also approved the Company's 2008 new Stock Option Plan. \nDetails regarding the new plan are contained in the Company's Information\nCircular dated Oct. 28, 2008, filed on SEDAR at www.sedar.com.\n\n\n\nResearch & Development Update\n\n\n\nThe Company is continuing its efforts toward milestone investigational\nnew drug application (IND) filings in the United States for L-DOS47 and\nTopical Interferon Alpha-2b, in its cervical dysplasia indication, by the end\nof its 2009 fiscal year ending July 31, 2009.\n\n\n\nL-DOS47\n\n\n\nHelix intends to conduct a pre-IND meeting with the FDA to confirm its\nNorth American Phase I program plans for L-DOS47. The Company expects the\npre-IND meeting to occur in the beginning of the 2009 calendar year. Pending\nthe positive outcome of the pre-IND meeting and timely success of the ongoing\nand remaining pre-clinical and manufacturing preparatory initiatives, the\nPhase I IND filing for this program is anticipated to occur sometime before\nthe end of Helix's fiscal fourth quarter, ending July 31, 2009. In addition,\nHelix is considering conducting a parallel confirmatory Phase I program in\nEurope, and is actively investigating the necessary regulatory filing\nrequirements to facilitate this in this same time period.\n\n\n\n\n\nHelix's objective for the commercialization of L-DOS47 is to enter into a\nstrategic alliance with a large pharmaceutical company at some point in the\nfuture. Before doing so, Helix plans to endeavor to generate value-adding\nclinical findings demonstrating the safety and efficacy of L-DOS47 in\npatients. Helix believes that there is a substantial market opportunity for\nL-DO...